This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pershadsingh, H. A. Articles by Kurtz, T. W. Search for Related Content PubMed PubMed Citation Articles by Pershadsingh, H. A. Articles by Kurtz, T. W.

Hypertension, Vol 21, 1020-1023, Copyright © 1993 by American Heart Association

ARTICLES

Effects of ciglitazone on blood pressure and intracellular calcium metabolism

HA Pershadsingh, J Szollosi, S Benson, WC Hyun, BG Feuerstein and TW Kurtz
Department of Family Practice, Kern Medical Center, Bakersfield, Calif.

Ciglitazone is the prototype of the thiazolidinedione class of compounds currently being developed for the treatment of insulin resistance and non-insulin-dependent diabetes. The effects of thiazolidinediones on blood pressure and cell calcium metabolism are not well defined. In the obese Zucker rat, a widely studied model of insulin resistance associated with mild hypertension, we investigated the effects of ciglitazone on plasma insulin levels and mean arterial pressure. We also evaluated the effects of ciglitazone on the changes in cytosolic calcium induced by platelet-derived growth factor in A172 human glioblastoma cells and rat A10 vascular smooth muscle cells. Oral administration of ciglitazone, approximately 45 mg/kg per day for 4 weeks, induced significant reductions in plasma insulin levels (p < 0.001) and blood pressure (p < 0.05). Ciglitazone was also found to significantly attenuate the capacity of platelet-derived growth factor BB homodimer to induce sustained increases in intracellular free calcium. These findings suggest that thiazolidinediones may offer a novel pharmacological approach to the treatment of hypertension, and raise the possibility that these compounds may affect blood pressure not only by affecting insulin metabolism but also by modifying the cell calcium response to pressor agents, growth factors, or both.

This article has been cited by other articles:

				P. Iglesias and J. J Diez Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur. J. Endocrinol., May 1, 2006; 154(5): 613 - 621. [Abstract] [Full Text] [PDF]

				M. J. Ryan, S. P. Didion, S. Mathur, F. M. Faraci, and C. D. Sigmund PPAR{gamma} Agonist Rosiglitazone Improves Vascular Function and Lowers Blood Pressure in Hypertensive Transgenic Mice Hypertension, March 1, 2004; 43(3): 661 - 666. [Abstract] [Full Text] [PDF]

				M. Iglarz, R. M. Touyz, F. Amiri, M.-F. Lavoie, Q. N. Diep, and E. L. Schiffrin Effect of Peroxisome Proliferator-Activated Receptor-{alpha} and -{gamma} Activators on Vascular Remodeling in Endothelin-Dependent Hypertension Arterioscler Thromb Vasc Biol, January 1, 2003; 23(1): 45 - 51. [Abstract] [Full Text] [PDF]

				T. W. Kurtz and D. G. Gardner Transcription-Modulating Drugs : A New Frontier in the Treatment of Essential Hypertension Hypertension, September 1, 1998; 32(3): 380 - 386. [Abstract] [Full Text] [PDF]

				J. W. Moore, M. A. Maher, W. J. Banz, and M. B. Zemel Chromium Picolinate Modulates Rat Vascular Smooth Muscle Cell Intracellular Calcium Metabolism J. Nutr., February 1, 1998; 128(2): 180 - 184. [Abstract] [Full Text]

				J. C. Clapham and N. C. Turner Effects of the Glucocorticoid II Receptor Antagonist Mifepristone on Hypertension in the Obese Zucker Rat J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1503 - 1508. [Abstract] [Full Text]

				T. A. Kotchen Attenuation of Hypertension by Insulin-Sensitizing Agents Hypertension, August 1, 1996; 28(2): 219 - 223. [Full Text]